Preparing for Future Wars
Against Life-Threatening Diseases*Opening new possibilities in treatment with next-generation mRNA platforms
Mission Statement + Technology Overview

We strive to address some of the biggest challenges in human health today

mRNA Platform Technology

We use proprietary UTR and Poly(A) optimization to create a stable, high-efficiency system maximizing mRNA's therapeutic potential.

LNP Delivery System

Our extensive in-house library of high-efficiency, low-toxicity Lipid Nanoparticles ensures safe and effective delivery to target cells.

In vivo Protein Therapeutics

Our approach enables the body to internally produce therapeutic proteins, like antibodies, eliminating the need for external manufacturing.

Personalized Cancer Vaccines

We develop patient-tailored vaccines designed to powerfully activate the immune system for effective cancer cell targeting.

Our Pipeline

Pipeline Snapshot

Next-Gen mRNA Platform

Achieves high stability and expression efficiency through proprietary mRNA sequence design technology and optimized UTR·Poly(A) tail.

AI-based sequence optimization

High-stability mRNA design

Applicable to diverse indications

Explore Platform →

Advanced LNP Technology

Safely delivers mRNA to target cells using a high-efficiency, low-toxicity LNP delivery system.

Owns proprietary LNP library

Track record of technology transfer to the Ministry of Food and Drug Safety

Ensures target specificity

Learn More →

About Us

SML Biopharm is an mRNA biotech company founded in 2021 as a university spin-off by Professor Nam Jae-hwan of The Catholic University of Korea.

Leveraging over a decade of mRNA research experience,
we provide new hope to patients suffering from diseases without existing treatments.

Meet Our Team →
PR

Press Release

services

What we do

Immunotherapy

Development of novel vaccines and cancer vaccines through mRNA-based immune response induction

In vivo Protein Therapeutics

Treatment of infectious diseases, cancer, and genetic disorders by directly expressing specific proteins (antibodies, enzymes, etc.) within the body

Personalized Medicine

Development of tailored therapeutics customized to each patient's unique characteristics

Founded

Global Partners

Years R&D

Pipeline Progress

Pipeline Overview

Advancing mRNA Therapeutics

g

Immunotherapy

b

Antibody Therapeutics

w

Protein Expression

*Development stages as of 2025